Loading…
Praxis Precision Medicines, Inc. is projected to rise to $401.22 by 2027, a +23% move from its current price of $324.99. PRAX is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $314.02 | $325.33 | $337.04 | +0.10% |
| Jul 14 | $309.78 | $325.66 | $342.37 | +0.21% |
| Jul 15 | $306.63 | $326.00 | $346.60 | +0.31% |
| Jul 16 | $304.05 | $326.34 | $350.26 | +0.42% |
| Jul 17 | $301.84 | $326.68 | $353.56 | +0.52% |
| Jul 18 | $299.88 | $327.02 | $356.61 | +0.62% |
| Jul 19 | $298.11 | $327.36 | $359.47 | +0.73% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $298.11 | $327.36 | $359.47 | +0.73% |
| Week 2 | $288.87 | $329.74 | $376.40 | +1.46% |
| Week 3 | $282.45 | $332.14 | $390.58 | +2.20% |
| Week 4 | $277.46 | $334.56 | $403.42 | +2.95% |
| Week 5 | $273.37 | $337.00 | $415.43 | +3.69% |
| Week 6 | $269.92 | $339.45 | $426.90 | +4.45% |
| Week 7 | $266.94 | $341.92 | $437.98 | +5.21% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Praxis Precision Medicines, Inc. is a clinical-stage biopharmaceutical company focused on central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance in the United States. Its Cerebrum platform develops orally available precision therapies for CNS small molecules, and Solidus supports antisense oligonucleotide discovery and development.
Praxis is advancing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in NDA for the treatment of essential tremor; relutrigine, a small molecule in NDA for the treatment of SCN2A- and SCN8A-developmental and epileptic encephalopathies (DEE), as well as in Phase 3 trial for broad DEEs; vormatrigine, a small molecule targeting hyperexcitable brain sodium-channels, in Phase 3 trial for adjunctive focal epilepsy and in Phase 2 for monotherapy focal epilepsy; and Elunsersen, a clinical-stage ASO designed to selectively decrease SCN2A gene expression, in Phase 3 for SCN2A-DEE. The company is also developing pre-clinical candidates including PRAX-020, PRAX-080, PRAX-090, and PRAX-100, with a cooperation and license agreement with RogCon Inc. and a research collaboration, option, and license with Ionis Pharmaceuticals, Inc.
Praxis Precision Medicines was formerly known as EpiPM Therapeutics, Inc., and changed its name in October 2016 after being incorporated in 2015. The company is headquartered in Boston, Massachusetts.
Praxis Precision Medicines, Inc. (PRAX) is a healthcare stock with a current price of $327.86 and a market cap of $9.14B, ranking 979. The stock trades in a market environment with a bullish technical backdrop and a 30-day trading range of $249.86 to $430.21.
A major floor 40.3% below — a decisive break under it would weaken the trend.
The nearest floor, 25.9% below — buyers have tended to step in here.
The nearest ceiling, 8.5% above — a clean break opens room to run.
A major ceiling 28.6% above — clearing it would confirm fresh momentum.
Key PRAX support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PRAX market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $325.71 | Sell | $326.91 | Sell |
| MA 10 | $327.98 | Sell | $322.70 | Buy |
| MA 20 | $305.70 | Buy | $314.73 | Buy |
| MA 50 | $313.58 | Buy | $311.45 | Buy |
| MA 100 | $316.21 | Buy | $302.16 | Buy |
| MA 200 | $264.93 | Buy | $260.79 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 54.96 | Neutral |
| Stoch RSI (14) | 18.22 | Buy |
| CCI (20) | 51.81 | Neutral |
| Williams %R (14) | -54.21 | Info |
| MACD (12,26,9) | 3.08 | Buy |
| ROC (12) | 6.42 | Buy |
| Bollinger %B (20,2) | 0.66 | Neutral |
| Stochastic %K (14) | 45.79 | Neutral |
| TRIX (15) | 0.20 | Buy |
| Awesome (5,34) | 21.19 | Buy |
| Ultimate (7,14,28) | 48.35 | Neutral |
| Momentum (10) | -2.87 | Sell |
| Aroon Osc (25) | 48.00 | Buy |
| Hull MA (9) | 330.27 | Sell |
| ADX (14) | 16.73 | Neutral |
| ATR (14) | 9.62 | Info |
Technically, the stock shows a bullish backdrop with RSI14 at 60 and price above both the 50-day and 200-day moving averages—SMA50 is $315.00 and SMA200 is $250.63. Near-term support sits at $240.66 and resistance at $357.13, framing a 30-day range from $249.86 to $430.21. Annualized volatility stands at 80, indicating elevated price movement within the period.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $240.66 | $324.99 | $462.75 | 0% | Neutral | |
| $310.67 | $401.22 | $553.16 | +23% | Bullish | |
| $337.00 | $451.77 | $652.14 | +39% | Bullish | |
| $496.24 | $686.34 | $1,026.72 | +111% | Bullish | |
| $578.31 | $822.37 | $1,267.44 | +153% | Bullish | |
| $604.95 | $882.45 | $1,395.73 | +172% | Bullish | |
| $700.21 | $1,046.10 | $1,693.26 | +222% | Bullish | |
| $701.87 | $1,072.51 | $1,772.60 | +230% | Bullish | |
| $750.80 | $1,172.29 | $1,974.92 | +261% | Bullish | |
| $905.42 | $1,443.36 | $2,475.00 | +344% | Bullish | |
| $1,287.74 | $2,259.25 | $4,170.02 | +595% | Bullish | |
| $2,919.01 | $6,082.68 | $12,479.75 | +17.7x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $240.66 | $324.99 | $391.38 | +0.00% |
| August 2026 | $288.05 | $342.67 | $420.52 | +5.44% |
| September 2026 | $297.53 | $357.21 | $444.64 | +4.24% |
| October 2026 | $290.89 | $352.01 | $443.42 | -1.46% |
| November 2026 | $287.58 | $350.33 | $445.72 | -0.48% |
| December 2026 | $294.01 | $360.41 | $462.75 | +2.88% |
Click any year to see its month-by-month PRAX forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The PRAX price prediction for 2026 points to an average of $324.99 (low $240.66, high $462.75) — a potential gain of 0% on today's $324.99. Price action looks broadly range-bound.
In 2027, PRAX is projected to trade between $310.67 and $553.16, averaging $401.22 — a potential gain of +23% from today's $324.99. That is up +23% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Praxis Precision Medicines, Inc.'s 2028 outlook centres on $451.77, within a $337.00 to $652.14 range. That is up +13% on the projected 2027 average. That marks a +39% change versus current levels. Momentum favours further upside here.
By 2029, PRAX could reach as high as $1,026.72, with a base case around $686.34 and support toward $496.24 — roughly +111% from $324.99. Buyers look set to stay in control over this stretch.
Expect PRAX to range from $578.31 to $1,267.44 through 2030. The $822.37 average target implies a +153% move from current prices. That is up +20% on the projected 2029 average. Momentum favours further upside here.
The PRAX price prediction for 2031 points to an average of $882.45 (low $604.95, high $1,395.73) — a potential gain of +172% on today's $324.99. Buyers look set to stay in control over this stretch.
In 2032, PRAX is projected to trade between $700.21 and $1,693.26, averaging $1,046.10 — a potential gain of +222% from today's $324.99. That is up +19% on the projected 2031 average. Momentum favours further upside here.
Praxis Precision Medicines, Inc.'s 2033 outlook centres on $1,072.51, within a $701.87 to $1,772.60 range. That is up +3% on the projected 2032 average. That marks a +230% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, PRAX could reach as high as $1,974.92, with a base case around $1,172.29 and support toward $750.80 — roughly +261% from $324.99. Momentum favours further upside here.
Expect PRAX to range from $905.42 to $2,475.00 through 2035. The $1,443.36 average target implies a +344% move from current prices. That is up +23% on the projected 2034 average. Buyers look set to stay in control over this stretch.
The PRAX price prediction for 2040 points to an average of $2,259.25 (low $1,287.74, high $4,170.02) — a potential gain of +595% on today's $324.99. Momentum favours further upside here.
In 2050, PRAX is projected to trade between $2,919.01 and $12,479.75, averaging $6,082.68 — a potential gain of +17.7x from today's $324.99. That is up +169% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in PRAX today (≈ 3.077018 PRAX) could be worth
$18,716.53
+$17,716.53 (+1772%) by 2050 · US Dollar
Based on the average projected PRAX price of $6,082.68 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PRAXwould be worth at today's price.
$1,000 invested in PRAX on Jul 10, 2025 (≈ 19.880716 PRAX) would be worth
$6,461.03
+$5,461.03 (+546.1%) today · 6.46× · US Dollar
Based on a PRAX entry price of $50.3 vs. today's $324.99.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $318.52 | $1,020.31 | +2.0% |
| 1 month ago | $240.66 | $1,350.41 | +35.0% |
| 3 months ago | $316.14 | $1,027.99 | +2.8% |
| 6 months ago | $275.74 | $1,178.61 | +17.9% |
| 1 year ago | $50.3 | $6,461.03 | +546.1% |
| All time (5.0y) ago | $282.9 | $1,148.78 | +14.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PRAX forecast.
Our base-case forecast reaches $650.00 around 2029.
Implied market cap at $650.00: $18.12B
The multi-year forecast displays a strong upside trajectory. In 2026, the min price is $240.66, the avg price is $327.86, the max price is $479.78, with an ROI of 0 and aNeutral sentiment. By 2030, the min is $590.61, the avg is $875.38, the max is $1,406.24, with an ROI of 167 and a bullish sentiment.
The forecast rises further to 2040 with a min of $1,340.21, an avg of $2,578.17, and a max of $5,054.20, yielding a 686.4 ROI and bullish sentiment, and then to 2050 with a min of $3,147.29, an avg of $6,993.98, and a max of $15,387.45, yielding a 2033.2 ROI and bullish sentiment. Overall, the forecast points to substantial long-term appreciation, though these figures are estimates and not guarantees. Drivers and risks are not provided in the data; the outlook should be viewed as one possible path among many.
Tap a question to reveal the answer.
The 2030 forecast shows an avg price of $875.38 with a min of $590.61 and a max of $1,406.24. The ROI is 167 and the sentiment is bullish.
The long-range forecast shows bullish sentiment from 2027 onward, with substantial upside through 2030, 2040, and 2050 (e.g., avg prices of $875.38 in 2030, $2,578.17 in 2040, and $6,993.98 in 2050). However, the 2026 year is neutral and the figures are estimates, not guarantees.
Yes. The 2033 forecast shows a max price of $1,964.86, with an avg of $1,131.87 and a min of $699.53; the ROI is 245.2 and the sentiment is bullish.
RSI14 is 60. SMA50 is $315.00 and SMA200 is $250.63. The stock sits with support at $240.66 and resistance at $357.13, within a 30-day range of $249.86 to $430.21, and there is an annualized volatility of 80.
The current price is $327.86 and the market cap is $9.14B. The stock is ranked 979.
Praxis Precision Medicines, Inc. Community Discussion
0Share your Praxis Precision Medicines, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.